PMID- 24024177
OWN - NLM
STAT- MEDLINE
DCOM- 20150409
LR  - 20220408
IS  - 2213-2317 (Electronic)
IS  - 2213-2317 (Linking)
VI  - 1
IP  - 1
DP  - 2013 Aug 1
TI  - Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-kappaB 
      pathways in diabetic neuropathy.
PG  - 394-7
LID - 10.1016/j.redox.2013.07.005 [doi]
AB  - The Nuclear factor-2 erythroid related factor-2 (Nrf2) is a redox regulated 
      transcription factor involved in the regulation of antioxidant defence systems. 
      It drives the production of endogenous antioxidant defences and detoxifying 
      enzymes. Nuclear factor-kappa light chain enhancer of B cells (NF-kappaB) is a 
      transcription factor, involved in proinflammatory cytokine production, in 
      addition to its immunological function. Both Nrf2 and NF-kappaB regulation are 
      co-ordinated in order to maintain redox homeostasis in healthy cells. However, 
      during pathological conditions this regulation is perturbed offering an 
      opportunity for therapeutic intervention. Diabetic neuropathy is a condition, in 
      which change in expression pattern of Nrf2 and NF-kappaB has been reported. This 
      review aims to focus on the role of the Nrf2 and NF-kappaB in diabetic neuropathy and 
      summarizes the therapeutic outcomes of various pharmacological modulators 
      targeted at the Nrf2-NF-kappaB axis in diabetic neuropathy.
FAU - Ganesh Yerra, Veera
AU  - Ganesh Yerra V
AD  - Department of Pharmacology and Toxicology, National Institute of Pharmaceutical 
      Education and Research (NIPER)-Hyderabad, Bala Nagar, India.
FAU - Negi, Geeta
AU  - Negi G
FAU - Sharma, Shyam S
AU  - Sharma SS
FAU - Kumar, Ashutosh
AU  - Kumar A
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130801
PL  - Netherlands
TA  - Redox Biol
JT  - Redox biology
JID - 101605639
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Animals
MH  - Diabetic Neuropathies/*drug therapy/*metabolism
MH  - Humans
MH  - NF-E2-Related Factor 2/*antagonists & inhibitors/metabolism
MH  - NF-kappa B/*antagonists & inhibitors/metabolism
PMC - PMC3757712
OTO - NOTNLM
OT  - Diabetic neuropathy
OT  - NF-kappaB
OT  - Nrf2
EDAT- 2013/09/12 06:00
MHDA- 2013/09/12 06:01
PMCR- 2013/08/01
CRDT- 2013/09/12 06:00
PHST- 2013/07/01 00:00 [received]
PHST- 2013/07/25 00:00 [revised]
PHST- 2013/07/25 00:00 [accepted]
PHST- 2013/09/12 06:00 [entrez]
PHST- 2013/09/12 06:00 [pubmed]
PHST- 2013/09/12 06:01 [medline]
PHST- 2013/08/01 00:00 [pmc-release]
AID - REDOX56 [pii]
AID - 10.1016/j.redox.2013.07.005 [doi]
PST - epublish
SO  - Redox Biol. 2013 Aug 1;1(1):394-7. doi: 10.1016/j.redox.2013.07.005.